EGFR and lung adenocarcinoma: Patients with uncommon EGFR-mutated lung adenocarcinoma for whom treatment guidelines in 2019 and 2020 were lacking and who were treated with on-label targeted therapy demonstrated relatively high response rates and long PFS.